Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Aachen – page 26

1 286 clinical trials in Aachen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Aachen at a glance
1 286
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 286 trials in Aachen

Open in trial search

Acute myeloid leukaemia+1

Recruiting

Study Comparing Treosulfan and Melphalan with Fludarabine for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fludarabine
  • Sponsor:Technische Universitat Dresden

Colorectal cancer

Recruiting

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Rectal cancer

Recruiting

Study Comparing Surgery and Chemoradiotherapy with Capecitabine for Early Rectal Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting

Triple negative breast cancer

Recruiting

Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Unicancer

Colitis ulcerative+1

Recruiting

Study on Reducing Vedolizumab Dosage for Patients with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Vedolizumab
  • Sponsor:Amsterdam UMC Stichting

Acute myeloid leukaemia

Recruiting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Breast cancer+1

Recruiting

A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Universitaetsklinikum Ulm AöR

Intensive care

Recruiting

Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dalteparin Sodium
  • Sponsor:Region Hovedstaden

Acquired ATTR amyloidosis

Recruiting

Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Eidos Therapeutics Inc.

Peripheral arterial occlusive disease+1

Recruiting

Study on Low-Dose Colchicine for Patients with Peripheral Artery Disease to Reduce Cardiovascular Risks

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Appendicitis+4

Recruiting

Study on Using Gentamicin and Clindamycin to Prevent Abscesses After Surgery for Complicated Appendicitis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clindamycin
  • Sponsor:Amsterdam UMC Stichting

Paroxysmal nocturnal haemoglobinuria

Recruiting

Study on Optimizing Ravulizumab Dosing for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Radboud universitair medisch centrum Stichting

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Aachen

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on lymphoma treatments and various forms of breast cancer therapies, including studies of novel immunotherapy combinations for head and neck cancers.

  • Diffuse Large B-Cell Lymphoma
  • Triple-Negative Breast Cancer
  • Non-small Cell Lung Cancer

Advanced therapeutic approaches including targeted treatments and combination therapies are being evaluated for improved patient outcomes.

02 Cardiovascular Studies

Research targeting heart failure prevention and management of cardiovascular complications, with emphasis on innovative drug combinations and preventive treatments.

  • Heart Failure Prevention
  • Cardiovascular Disease Management
  • Obesity-related Cardiac Conditions

Studies focus on reducing cardiovascular events and improving long-term patient outcomes.

03 Chronic Conditions

Clinical investigations addressing various chronic conditions, including inflammatory diseases and dermatological disorders.

  • Hidradenitis Suppurativa
  • Chronic Venous Ulcers
  • Inflammatory Myopathies

Evaluating new therapeutic approaches for managing long-term conditions and improving quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.